Edoxaban, an oral anticoagulant, was equally or more effective than warfarin in reducing the risk of stroke and blood clots for patients after heart valve replacement surgery, according to ...

Edoxaban is administered once daily, whereas the approved pediatric dosing for other direct oral anticoagulants (DOACs) ranges from twice daily to three times per day, he noted.

Edoxaban, a reversible and direct inhibitor of factor Xa, is used to reduce the risk for stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). It is also used to ...

Edoxaban may be effective treatment for atrial fibrillation after transcatheter aortic valve replacement Date: August 29, 2021 Source: The Mount Sinai Hospital / Mount Sinai School of Medicine ...

However, major bleeding rates were lower for apixaban, driven by differences in gastrointestinal bleeding and other nonspecified bleeding (45.57 vs 31.21 per 1,000 person-years; adjusted HR 1.42 ...

Edoxaban was found to be noninferior to warfarin in patients with AF undergoing TAVR, a population that warranted further study. In places such as East Asia where edoxaban is used, it remains a ...

Extended treatment with the oral anticoagulant edoxaban prevented recurrent venous thromboembolism and led to fewer major bleeding events than warfarin among patients with venous thromboembolism ...

Edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic therapy, in patients with high-risk atrial ...

4 Consideration of the evidence. The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of edoxaban, having considered evidence on the nature of non‑valvular atrial ...

Male patients made up 51.3% and 62.4% of the edoxaban and warfarin arms, respectively. About one in five patients had AF, and the vast majority of patients had aortic valve surgery. About one-third of ...

"Edoxaban could make life easier for patients recovering from heart valve surgery," said study leader Dr. Chisato Izumi, of the National Cerebral and Cardiovascular Center in Suita, Japan.